Spotlight on Formulary Management
ACPE UAN: 0233-0000-19-031-L01-P | Contact Hours: 1.25 | Activity Type: Knowledge-based
Statement of Commercial Support: This educational activity is supported by an unrestricted educational grant from Actelion Pharmaceuticals, Inc.
Patients with pulmonary arterial hypertension (PAH) currently have a 60% five-year survival outlook, which has been increasing since the 1980s when it was a 37% five-year outlook. This is attributed to a growing understanding of PAH and improved treatments available for the disease. However, there is inconsistency in inter-provider placement of patients into PAH functional classification categories. This creates discrepancies in treatment options used and may increase indirect costs through patients not receiving the right type of treatment to improve functionality and reduce chances of developing comorbid conditions.
This session will provide data on the pathophysiology and potential comorbidities of PAH, WHO functional classification categories and how these impact treatment decisions, information on emerging therapies, and formulary management approaches for PAH.
At the completion of this activity, participants should be able to: